Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma Statistics

Total Valuation

Nuvectis Pharma has a market cap or net worth of $222.53 million. The enterprise value is $186.39 million.

Market Cap	222.53M
Enterprise Value	186.39M

Important Dates

The next estimated earnings date is Tuesday, May 5, 2026, before market open.

Earnings Date	May 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Nuvectis Pharma has 26.49 million shares outstanding. The number of shares has increased by 27.46% in one year.

Current Share Class	26.49M
Shares Outstanding	26.49M
Shares Change (YoY)	+27.46%
Shares Change (QoQ)	+2.10%
Owned by Insiders (%)	41.52%
Owned by Institutions (%)	17.21%
Float	15.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	11.48
P/TBV Ratio	11.84
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.38

Current Ratio	2.38
Quick Ratio	2.38
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -188.03% and return on invested capital (ROIC) is -122.55%.

Return on Equity (ROE)	-188.03%
Return on Assets (ROA)	-68.50%
Return on Invested Capital (ROIC)	-122.55%
Return on Capital Employed (ROCE)	-149.75%
Weighted Average Cost of Capital (WACC)	2.52%
Revenue Per Employee	n/a
Profits Per Employee	-$2.22M
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.78% in the last 52 weeks. The beta is -0.32, so Nuvectis Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.32
52-Week Price Change	-20.78%
50-Day Moving Average	8.66
200-Day Moving Average	7.37
Relative Strength Index (RSI)	38.38
Average Volume (20 Days)	55,110

Short Selling Information

The latest short interest is 1.62 million, so 6.12% of the outstanding shares have been sold short.

Short Interest	1.62M
Short Previous Month	1.65M
Short % of Shares Out	6.12%
Short % of Float	10.46%
Short Ratio (days to cover)	27.13

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-27.57M
Pretax Income	-26.44M
Net Income	-28.87M
EBITDA	n/a
EBIT	-27.57M
Earnings Per Share (EPS)	-$1.32

Balance Sheet

The company has $31.63 million in cash and n/a in debt, with a net cash position of $31.63 million or $1.19 per share.

Cash & Cash Equivalents	31.63M
Total Debt	n/a
Net Cash	31.63M
Net Cash Per Share	$1.19
Equity (Book Value)	18.41M
Book Value Per Share	0.72
Working Capital	18.41M

Cash Flow

Operating Cash Flow	-16.01M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nuvectis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-27.46%
Shareholder Yield	-27.46%
Earnings Yield	-13.24%
FCF Yield	n/a

Analyst Forecast

The average price target for Nuvectis Pharma is $15.33, which is 82.50% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$15.33
Price Target Difference	82.50%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2